Teva Pharma Replaces ADRs with Ordinary Shares on NYSE
Teva Pharmaceutical Industries announced a significant structural change, transitioning from trading American Depositary Receipts (ADRs) to its ordinary shares on the New York Stock Exchange (NYSE) starting September 14. This move effectively eliminates the ADR program, with each ADR being converted into one ordinary share. While the ticker symbol TEVA remains the same and the stock continues to trade in Tel Aviv, the change signifies a move away from the traditional structure used by foreign companies to list on Wall Street.
Previously, ADRs represented shares held by a trustee bank, adding an intermediary layer that incurred annual fees and operational friction, particularly concerning dividends and voting rights. The elimination of this layer means the shares traded in New York are now identical to those traded in Tel Aviv, simplifying arbitrage between the two markets and potentially aligning their prices more closely.
This structural shift is particularly relevant for institutional investors in the United States, as some investment mandates restrict or prohibit holdings in ADRs. By trading ordinary shares, Teva may broaden its investor base, as index providers and funds may now classify the stock differently, potentially improving liquidity and accessibility.
The company's transition follows a series of positive developments, including regaining an investment-grade credit rating from S&P, Fitch, and Moody's, and successfully raising approximately $4.9 billion in dollar and euro bonds. This debt issuance aims to refinance more expensive existing debt and reflects Teva's improved financial standing.
Strategically, Teva is advancing its "Pivot to Growth" plan, focusing on innovative medicines, biosimilars, and pipeline products, such as Austedo, Ajovy, and UZEDY, alongside maintaining a stable generics business. The company anticipates significant revenue potential from its innovative drug pipeline, with several products expected to launch by mid-2027.
